MapLight Therapeutics Management
Management criteria checks 2/4
MapLight Therapeutics' CEO is Chris Kroeger, appointed in Jan 2018, has a tenure of 8.67 years. total yearly compensation is $25.62M, comprised of 2.6% salary and 97.4% bonuses, including company stock and options. directly owns 0.47% of the company’s shares, worth $3.59M. The average tenure of the management team and the board of directors is 5.8 years and 3.2 years respectively.
Key information
Chris Kroeger
Chief executive officer
US$25.6m
Total compensation
| CEO salary percentage | 2.56% |
| CEO tenure | 8.7yrs |
| CEO ownership | 0.5% |
| Management average tenure | 5.8yrs |
| Board average tenure | 3.2yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2026 | n/a | n/a | -US$230m |
| Mar 31 2026 | n/a | n/a | -US$199m |
| Dec 31 2025 | US$26m | US$655k | -US$161m |
| Sep 30 2025 | n/a | n/a | -US$103m |
| Jun 30 2025 | n/a | n/a | -US$92m |
| Mar 31 2025 | n/a | n/a | -US$81m |
| Dec 31 2024 | US$9m | US$628k | -US$78m |
| Mar 31 2024 | n/a | n/a | -US$63m |
| Dec 31 2023 | US$5m | US$602k | -US$56m |
Compensation vs Market: Chris's total compensation ($USD25.62M) is above average for companies of similar size in the US market ($USD3.53M).
Compensation vs Earnings: Chris's compensation has increased whilst the company is unprofitable.
CEO
Chris Kroeger (58 yo)
Dr. Christopher A. Kroeger, also known as Chris, M.D., Ph D., MBA is Founder of MapLight Therapeutics, Inc. and has been its President, Chief Executive Officer and Director from 2018. He serves as Director...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 8.7yrs | US$25.62m | 0.47% $ 3.6m | |
| Co-Founder & Member of Scientific Advisory Board | no data | US$3.22m | 0.39% $ 3.0m | |
| Chief Medical Officer | 5.3yrs | US$6.25m | 0.56% $ 4.3m | |
| Founder & Member of Advisory Board | no data | no data | no data | |
| Co-Founder & Member of Scientific Advisory Board | no data | no data | no data | |
| Chief Admin & Acc Officer | 2.5yrs | no data | 0% $ 0 | |
| Chief Scientific Officer | 7.6yrs | no data | 0.080% $ 612.4k | |
| General Counsel & Secretary | 3.4yrs | no data | 0.029% $ 223.7k | |
| Chief Discovery Officer | 6.3yrs | no data | 0.037% $ 279.9k |
Experienced Management: MPLT's management team is seasoned and experienced (5.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 8.7yrs | US$25.62m | 0.47% $ 3.6m | |
| Co-Founder & Member of Scientific Advisory Board | no data | US$3.22m | 0.39% $ 3.0m | |
| Founder & Member of Advisory Board | no data | no data | no data | |
| Co-Founder & Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Chairman of the Board | 7.6yrs | US$9.66k | 0.045% $ 344.6k | |
| Independent Director | 2.6yrs | US$895.18k | 0.013% $ 103.2k | |
| Independent Director | 3.2yrs | US$728.40k | 0.12% $ 931.6k | |
| Independent Director | 1.2yrs | US$10.58k | no data | |
| Independent Director | less than a year | no data | 0.042% $ 323.8k | |
| Member of Scientific Advisory Board | 3.4yrs | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data |
Experienced Board: MPLT's board of directors are considered experienced (3.2 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/09/11 21:56 |
| End of Day Share Price | 2026/09/11 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
MapLight Therapeutics, Inc. is covered by 14 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Malcolm Hoffman | BMO Capital Markets Equity Research |
| Sumant Satchidanand Kulkarni | Canaccord Genuity |
| Adam Vogel | Craig-Hallum Capital Group LLC |